Raymond Kelleher, MD, PhD
Raymond (‘Ray’) Kelleher is an accomplished clinician-scientist, company founder, and investor. He represents Cormorant Asset Management on the board.
Ray is Managing Director at Cormorant Asset Management, where he is responsible for investing in public and private companies across all therapeutic areas. He also represents Cormorant on the boards of Arkuda Therapeutics, BiVACOR, and Expansion Therapeutics as Director, and Chroma Therapeutics, Umoja Biopharma, Interius BioTherapeutics, Garuda Therapeutics, and DTx Pharma as Observer.
Ray also maintains an active clinical practice at Massachusetts General Hospital focused on neurodegenerative disorders, particularly Alzheimer’s disease and related dementias. In addition, he is a faculty member at Massachusetts General Hospital and Harvard Medical school, where he previously completed his internship in internal medicine and residency in neurology. He now leads a research group making important contributions towards understanding the molecular and cellular basis of cognition and cognitive disorders.
Earlier in his career Ray conducted postdoctoral research at Massachusetts Institute of Technology (MIT) with Nobel Laureate Susumu Tonegawa, where he discovered a key role for translational control in memory formation.
Ray’s work has been published in Cell, Nature, Neuron, PNAS, and other high impact journals, and his research accomplishments have been recognized with national awards including the Pew Scholars Award in the Biomedical Sciences, the John Merck Scholars Award, and the NIH Independent Scientist Award.
Ray received BS degrees in Biology and Literature from MIT, an MA in French from Harvard University, and an MD and PhD in Cell Biology from Stanford University.